• P-ISSN2233-4203
  • E-ISSN2093-8950

Article Detail

Home > Article Detail
  • P-ISSN 2233-4203
  • E-ISSN 2093-8950

LC-MS/MS Method for Simultaneous Analysis of Growth Hormone-Releasing Peptides and Secretagogues in Human Urine

Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2016, v.7 no.3, pp.55-63
https://doi.org/10.5478/MSL.2016.7.3.55
Min Hophil (Korea Institute of Science and Technology)
Han Boyoung (Korea Institute of Science and Technology)
Sung Changmin (Korea Institute of Science and Technology)
Park Ju-Hyung (Korea Institute of Science and Technology)
Lee Kang Mi (Korea Institute of Science and Technology)
Kim Ho Jun (Korea Institute of Science and Technology)
Kim Ki Hun (Korea Institute of Science and Technology)
Son Junghyun (Korea Institute of Science and Technology)
Oh-SeungKwon (Korea Institute of Science and Technology)
Jaeick Lee (Korea Institute of Science and Technology)
  • Downloaded
  • Viewed

Abstract

Growth hormone (GH)-releasing peptides (GHRPs) and GH secretagogues (GHSs) are listed in the World Anti-Doping Agency (WADA) Prohibited List. In the present study, we developed and validated a method for the simultaneous analysis of seven GHRPs (alexamorelin, GHRP-1, -2, -4, -5, -6, and hexarelin) and three GHSs (anamorelin, ibutamoren, and ipamorelin) in human urine. Method validation was performed at minimum required performance levels specified by WADA technical documents (2 ng/mL) for all substances, and the method was validated with regard to selectivity (no interference), linearity (R2 > 0.9986), matrix effects (50.0%-141.2%), recovery (10.4%-100.8%), and intra- (2.8%-16.5%) and inter-day (7.0%-22.6%) precisions. The limits of detection for screening and confirmation were 0.05-0.5 ng/mL and 0.05-1 ng/mL, respectively.

keywords
Doping control analysis Growth hormone GHRP GHS Method validation


Reference

1

Saugy, M.. (2006). . Brit J. Sport Med, 40(Suppl 1), i35-.

2

Saugy, M.. (1996). . J. Chromatogr. B, 687, 201-.

3

Baumann, G. P.. (2012). . Endocr. Rev, 33, 155-.

4

Bowers, C. Y.. (1991). . Endocrinology, 128, 2027-.

5

Arvat, E.. (2001). . J. Clin. Endocr. Metab, 86, 1169-.

6

Okano, M.. (2010). . Drug Test Anal, 2, 548-.

7

Garcia, J. M.. (2009). . Growth Horm. Igf. Res, 19, 267-.

8

Svensson, J.. (2003). . Growth Horm Igf. Res, 13, 1-.

9

Thomas, A.. (2011). . Anal. Bioanal. Chem, 401, 507-.

10

Okano, M.. (2010). . Rapid Commun. Mass Spectrom, 24, 2046-.

11

Thomas, A.. (2012). . Anal. Chem, 84, 10252-.

12

Sobolevsky, T.. (2014). . Drug Test Anal, 6, 1087-.

13

Mazzarino, M.. (2015). . Forensic Toxicol, 33, 321-.

14

World Anti-Doping Agency. (2015). Technical Document for minimum required performance levels. https://www.wada-ama.org/en/resources/science-medicine/td2015-mrpl.

Submission Date
2016-08-11
Revised Date
2016-09-29
Accepted Date
2016-09-29
상단으로 이동

Mass Spectrometry Letters